The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies

BACKGROUND: For psoriatic patients receiving biologics, the concern of tuberculosis (TB) infection exists. Although the TB risk of anti-interleukin (IL)-17A agents is generally considered very low, more real-world data are needed to support the safety. OBJECTIVES: This study aims to provide the real...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chen-Yu, Chiu, Hsien-Yi, Tsai, Tsen-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934285/
https://www.ncbi.nlm.nih.gov/pubmed/31881026
http://dx.doi.org/10.1371/journal.pone.0225112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934285/
https://www.ncbi.nlm.nih.gov/pubmed/31881026
http://dx.doi.org/10.1371/journal.pone.0225112

Ejemplares similares